Abstract:Recent studies suggest that 40Hz photoacoustic stimulation is beneficial for improving cognition, and is safe and effective in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). It has been reported that the healthy population responds more strongly to the 40 Hz intervention compared to MCI and AD patients. Therefore, the aim of this study was to explore the effectiveness of 40 Hz photoacoustics in preventing cognitive impairment and improving sleep quality in the healthy population. Four weeks of 40 Hz intervention significantly improved sleep quality (PSQI) (p=0.028) and enhanced functional connectivity in the hippocampus and default mode network (DMN) (in the cognitively impaired population, functional connectivity showed a decreasing trend). These results were consistent with findings from the FDA clinical trial on MCI/AD patients that showed enhanced connectivity of the core regions PCC and mPFC within the DMN network. No serious adverse effects were reported throughout the intervention. This study is the first to validate the efficacy and safety of a 40 Hz photoacoustic intervention in a healthy population, suggesting its potential in preventing cognitive decline in a healthy population. ### Competing Interest Statement Zhuping Gong, Kaixiu Jin, Junhu Teng, Ziyu Liu, Huajiang Zhang, Qian Xu, Yanling Chen , and Cong Fang are staff members of Hangzhou Shudan Healthcare Technology Co. Ltd., which aims to develop gamma stimulation-related products. Other authors declare no other competing financial interests. ### Clinical Trial ChiCTR2300071558 ### Funding Statement This study did not receive any funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All participants gave written consent and the study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.

Exploring the impact of 40 Hz multi-luminaire light exposure in Alzheimer's dementia: insights from a convenient sampling, non-randomized case-control study

Aggregation of Vascular Risk Factors Modulates the Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment Patients

Effect of 40 Hz Light Flicker on Cognitive Impairment and Transcriptome of Hippocampus in Right Unilateral Common Carotid Artery Occlusion Mice

40HZ photoacoustic interventions combined with blue light improve brain function and sleep quality in a healthy population

Flickering Red-Light Stimulus for Promoting Coherent 40 Hz Neural Oscillation: A Feasibility Study

Non-invasive 40-Hz Light Flicker Ameliorates Alzheimer’s-Associated Rhythm Disorder via Regulating Central Circadian Clock in Mice

Non-invasive 40-Hz Light Flicker Ameliorates Alzheimer's-Associated Rhythm Disorder via Regulating Central Circadian Clock in Mice

A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

Effects of Morning Blue-Green 500 Nm Light Therapy on Cognition and Biomarkers in Middle-Aged and Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment: Study Protocol for a Randomized Controlled Trial.

Gamma Band Light Stimulation in Human Case Studies: Groundwork for Potential Alzheimer's Disease Treatment

A Pilot Study of Near-Infrared Light Treatment for Alzheimer’s Disease

Improvement of olfactory function in AD mice mediated by immune responses under 40 Hz light flickering

40 Hz light preserves synaptic plasticity and mitochondrial function in Alzheimer's disease model

The 40 Hz flickering light restores synaptic plasticity and mitochondrial phenotype in experimental model of Alzheimer's disease

Safety, Tolerability and Efficacy of 40 Hz Sensory Stimulation for Alzheimers Disease

Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease

Photobiomodulation's Potential as a Non-Invasive Therapy for Alzheimer's disease and Minimal Cognitive Impairment: A 12-Week Investigation

Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies

Frequency and duration of sensory flicker controls astrocyte and neuron specific transcriptional profiles in 5xFAD mice

Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies